Oncological Outcomes in Bacillus Calmette-Guérin–naïve High-risk Non–muscle-invasive Bladder Cancer Patients: A Systematic Review on Current Treatment Strategies and Future PerspectivesMattia Longoni, Marco Moschini, Évanguelos Xylinas et al.|European Urology Oncology|2025Cited by 43
Clinical Validation of the Intermediate-risk Non–muscle-invasive Bladder Cancer Scoring System and Substratification Model Proposed by the International Bladder Cancer Group: A Multicenter Young Academic Urologists Urothelial Working Group CollaborationFrancesco Soria, Paolo Gontero, Matteo Rosazza et al.|European Urology Oncology|2024Cited by 32
The Role of Mitomycin C in Intermediate-risk Non–muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysisPietro Scilipoti, Marco Moschini, Aleksander Ślusarczyk et al.|European Urology Oncology|2024Cited by 29
Efficacy of Different Bacillus of Calmette-Guérin (BCG) Strains on Recurrence Rates among Intermediate/High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): Single-Arm Study Systematic Review, Cumulative and Network Meta-AnalysisFrancesco Del Giudice, Ettore De Berardinis, Vincenzo Asero et al.|Cancers|2023Cited by 28
Unlocking the Potential of Adequate Bacillus Calmette-Guérin Immunotherapy in Very-high-risk Non–muscle-invasive Bladder Carcinoma: A Multicenter Analysis of Oncological Outcomes and Risk DynamicsJosé Daniel Subiela, F.J. Burgos Revilla, Wojciech Krajewski et al.|European Urology Oncology|2024Cited by 20